Mounjaro 12.5 mg is prescribed for the following medical indications: 🔹 Type 2 Diabetes Mellitus: Long-term blood sugar control in adult patients when previous doses (5 mg, 7.5 mg, 10 mg) did not provide sufficient glycemic control. 🔹 Weight Management: Treatment of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) in the presence of cardiovascular complications, hypertension, or dyslipidemia.

Dosage and administration

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 12.5 mg.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The drug is administered once a week. Transition to the 12.5 mg dose is only possible after successful completion of at least a 4-week course at the 10 mg dosage. Injection Technique: Subcutaneous injection into the abdomen, front of the thigh, or upper arm. Rotate the injection site weekly. Timing: Independent of meals. It is recommended to choose the same day of the week for ease of tracking. Storage: Store in the refrigerator at 2°C–8°C. Do not freeze! After starting use, the pen can be stored at temperatures up to 30°C for 21 days.

⛔ Oncological Risks: Personal or family history of medullary thyroid carcinoma. ⛔ Endocrine Diseases: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). ⛔ Pregnancy and Lactation: Use is contraindicated. When planning a pregnancy, use should be discontinued 2 months in advance. ⛔ Type 1 Diabetes Mellitus: Not intended for the treatment of this type of disease. ⛔ Severe GI Disorders: Severe gastroparesis or history of pancreatitis. ⛔ Allergy: Hypersensitivity to tirzepatide.

When using the 12.5 mg dosage, side effects related to the body's adaptation to a high concentration of the drug are possible: 🤢 Gastroenterological: Nausea, diarrhea, vomiting, dyspepsia, abdominal pain. Usually pronounced in the first weeks after a dose increase. 🍽️ Reduced Appetite: Rapid satiety and changes in taste preferences are frequently observed. 🏃♂️ General: Fatigue, feeling of weakness, sometimes dizziness (especially with low calorie intake). ⚠️ Serious Warnings: Monitoring of renal function is necessary in cases of severe vomiting (dehydration risk). Rarely — acute pancreatitis or gallbladder disease. 💉 Skin Reactions: Mild redness or itching at the injection site.

Mounjaro KwikPen 12.5 — Tirzepatide 12.5 mg, 1 pcs, Eli Lilly

100% original product

Active ingredient

Tirzepatide

Storage temperature

Cold chain · Storage +2…+8 °C

Shipped in a thermal box with cold packs

Manufacturer

Eli Lilly

Dosage

12.5 mg

Dosage form Prefilled pen

Pens per pack 1

Mounjaro KwikPen 12.5 — Tirzepatide 12.5 mg (1 Pen / 4 Doses) Cold chain · Storage +2…+8 °C

Name: Mounjaro KwikPen 12.5
Brand: Eli Lilly
SKU: PROD-271
Price: 19400 UAH
Availability: OutOfStock

19400₴ ~~22663₴~~ -14% Out of stock

Cold chain Storage +2…+8 °C

This medicine requires temperature control. We pack it in a thermal box with cold packs for safe delivery.

Please return the thermal box with cold packs after delivery. An additional charge applies only if you wish to keep the box.

Mounjaro KwikPen 12.5 mg (Tirzepatide) is a high-dose form of one of the most advanced medications for the treatment of type 2 diabetes and chronic weight management. Tirzepatide is unique as a dual receptor agonist: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The 12.5 mg dosage is intended for patients requiring intensive therapy to achieve target metabolic goals.

Manufacturer: Eli Lilly. The KwikPen format is a convenient multi-dose pre-filled pen containing a monthly course of the medication. The device is designed so that patients can perform injections independently and virtually painlessly with high dosing precision.

Key Features:

✅ Advanced Level of Therapy: 12.5 mg is one of the final steps in dose titration, providing powerful glycemic control and a significant reduction in body mass index.
✅ Dual Effect: Acting on two hormonal pathways allows for more effective appetite suppression and optimized insulin production compared to previous generation drugs.
✅ Economy and Convenience: One KwikPen replaces four individual old-style pens, providing 4 full weekly injections.

Mounjaro 12.5 mg is prescribed for the following medical indications:

🔹 Type 2 Diabetes Mellitus: Long-term blood sugar control in adult patients when previous doses (5 mg, 7.5 mg, 10 mg) did not provide sufficient glycemic control.
🔹 Weight Management: Treatment of obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) in the presence of cardiovascular complications, hypertension, or dyslipidemia.

Sales Form: 1 multi-dose KwikPen (2.4 ml of solution) containing 4 doses of 12.5 mg.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The drug is administered once a week. Transition to the 12.5 mg dose is only possible after successful completion of at least a 4-week course at the 10 mg dosage.
Injection Technique: Subcutaneous injection into the abdomen, front of the thigh, or upper arm. Rotate the injection site weekly.
Timing: Independent of meals. It is recommended to choose the same day of the week for ease of tracking.
Storage: Store in the refrigerator at 2°C–8°C. Do not freeze! After starting use, the pen can be stored at temperatures up to 30°C for 21 days.

⛔ Oncological Risks: Personal or family history of medullary thyroid carcinoma.
⛔ Endocrine Diseases: Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
⛔ Pregnancy and Lactation: Use is contraindicated. When planning a pregnancy, use should be discontinued 2 months in advance.
⛔ Type 1 Diabetes Mellitus: Not intended for the treatment of this type of disease.
⛔ Severe GI Disorders: Severe gastroparesis or history of pancreatitis.
⛔ Allergy: Hypersensitivity to tirzepatide.

When using the 12.5 mg dosage, side effects related to the body's adaptation to a high concentration of the drug are possible:

🤢 Gastroenterological: Nausea, diarrhea, vomiting, dyspepsia, abdominal pain. Usually pronounced in the first weeks after a dose increase.
🍽️ Reduced Appetite: Rapid satiety and changes in taste preferences are frequently observed.
🏃‍♂️ General: Fatigue, feeling of weakness, sometimes dizziness (especially with low calorie intake).
⚠️ Serious Warnings: Monitoring of renal function is necessary in cases of severe vomiting (dehydration risk). Rarely — acute pancreatitis or gallbladder disease.
💉 Skin Reactions: Mild redness or itching at the injection site.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.06.2026

Active ingredient

Tirzepatide